Core Viewpoint - Huadong Medicine's stock price has shown a mixed performance in recent trading sessions, with a year-to-date increase of 22.30% but a decline of 2.39% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Huadong Medicine achieved a revenue of 32.664 billion yuan, representing a year-on-year growth of 3.77% [2] - The net profit attributable to shareholders for the same period was 2.748 billion yuan, reflecting a year-on-year increase of 7.24% [2] Shareholder Information - As of September 30, 2025, the number of Huadong Medicine's shareholders decreased by 1.50% to 68,800, while the average number of circulating shares per person increased by 1.53% to 25,466 shares [2] - The company has cumulatively distributed 8.873 billion yuan in dividends since its A-share listing, with 3.771 billion yuan distributed over the last three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the third-largest circulating shareholder, holding 52.004 million shares, an increase of 12.1653 million shares from the previous period [3] - China Securities Finance Corporation remains the fourth-largest shareholder with 22.1868 million shares, unchanged from the previous period [3] - Notable changes in holdings include a decrease of 4.3243 million shares for the fifth-largest shareholder, China Universal Healthcare Mixed A [3]

Core Viewpoint - Jincheng Pharmaceutical's stock has shown a significant increase of 41.23% year-to-date, despite recent declines in the last five, twenty, and sixty trading days [1][2]. Company Overview - Jincheng Pharmaceutical, established on January 12, 2004, and listed on June 22, 2011, is located in Zibo City, Shandong Province. The company specializes in the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and finished formulations [2]. - The revenue composition of Jincheng Pharmaceutical includes: 34.59% from formulation products, 26.61% from other pharmaceutical chemical products, 21.88% from cephalosporin side chain active esters, and 16.92% from biopharmaceuticals and specialty APIs [2]. Financial Performance - For the period from January to September 2025, Jincheng Pharmaceutical reported revenue of 1.932 billion yuan, a year-on-year decrease of 23.19%, and a net profit attributable to shareholders of 31.577 million yuan, down 79.10% year-on-year [2]. - The company has distributed a total of 933 million yuan in dividends since its A-share listing, with 323 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Jincheng Pharmaceutical had 26,700 shareholders, an increase of 0.46% from the previous period, with an average of 13,903 circulating shares per shareholder, a decrease of 0.46% [2][3]. - Notable shareholders include the fourth-largest shareholder, Fortune Precision Medical Flexible Allocation Mixed A, holding 4.961 million shares, and the eighth-largest shareholder, Hong Kong Central Clearing Limited, holding 3.336 million shares, which decreased by 2.135 million shares from the previous period [3].

Core Viewpoint - Guanhao Biological has shown a mixed performance in stock price, with a year-to-date increase of 23.26% but a recent decline over the past five, twenty, and sixty days [1][2]. Company Overview - Guanhao Biological Technology Co., Ltd. was established on October 22, 1999, and listed on July 6, 2011. The company is located in Huangpu District, Guangzhou, Guangdong Province [1]. - The main business involves research, production, and sales of regenerative medical materials and implantable medical devices, as well as cell therapy technology development, preparation, clinical application, and immune cell storage [1]. - The revenue composition is as follows: medical devices 73.28%, pharmaceuticals 15.21%, and leasing and other services 11.51% [1]. Financial Performance - For the period from January to September 2025, Guanhao Biological achieved an operating income of 293 million yuan, representing a year-on-year growth of 5.52%. However, the net profit attributable to the parent company was 26.72 million yuan, a decrease of 4.02% year-on-year [2]. - The company has cumulatively distributed 86.66 million yuan since its A-share listing, with no distributions in the past three years [3]. Shareholder Information - As of November 10, 2025, the number of shareholders for Guanhao Biological was 29,600, an increase of 4.20% from the previous period. The average circulating shares per person decreased by 4.03% to 8,951 shares [2]. - The top ten circulating shareholders include a new entrant, the Medical Device ETF (159883), holding 1.31 million shares [3]. Market Activity - On November 24, the stock price increased by 2.27% to 14.84 yuan per share, with a trading volume of 9.44 million yuan and a turnover rate of 0.24%. The total market capitalization is 3.935 billion yuan [1]. - The net inflow of main funds was 856,700 yuan, with large orders accounting for 11.99% of total purchases [1].

Core Viewpoint - Huadong Medicine's stock price has experienced fluctuations, with a year-to-date increase of 19.81% but a recent decline of 6.51% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Huadong Medicine achieved a revenue of 32.664 billion yuan, representing a year-on-year growth of 3.77%, and a net profit attributable to shareholders of 2.748 billion yuan, up 7.24% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of Huadong Medicine's shareholders decreased by 1.50% to 68,800, while the average circulating shares per person increased by 1.53% to 25,466 shares [2] - The company has distributed a total of 8.873 billion yuan in dividends since its A-share listing, with 3.771 billion yuan distributed over the past three years [3] Stockholder Composition - The top circulating shareholder, Hong Kong Central Clearing Limited, increased its holdings by 12.1653 million shares to 52.0036 million shares [3] - China Securities Finance Corporation maintained its position as the fourth-largest shareholder with 22.1868 million shares, while other notable shareholders saw reductions in their holdings [3] Business Overview - Huadong Medicine, established on March 31, 1993, and listed on January 27, 2000, is primarily engaged in the production and sale of various pharmaceutical products, with a revenue composition of 64.45% from commercial activities and 39.69% from manufacturing [1] - The company operates in several sectors, including vitamins, traditional Chinese medicine, hepatitis treatment, pharmaceutical e-commerce, and medical aesthetics [1]

Core Viewpoint - The stock of Furuida has experienced a decline, with a current price of 7.75 yuan per share and a market capitalization of 7.878 billion yuan, reflecting a challenging financial performance in recent periods [1][2]. Company Performance - Furuida's stock price has increased by 3.33% year-to-date, but it has seen a decline of 3.00% over the last five trading days, 1.77% over the last 20 days, and 9.57% over the last 60 days [1]. - For the period from January to September 2025, Furuida reported a revenue of 2.597 billion yuan, a year-on-year decrease of 7.34%, and a net profit attributable to shareholders of 142 million yuan, down 17.19% year-on-year [2]. Shareholder and Market Activity - As of September 30, 2025, Furuida had 44,500 shareholders, a decrease of 6.27% from the previous period, with an average of 22,827 circulating shares per shareholder, an increase of 6.69% [2]. - The company has made cumulative cash distributions of 1.196 billion yuan since its A-share listing, with 213 million yuan distributed over the last three years [3]. Institutional Holdings - Among the top ten circulating shareholders, the Southern CSI 1000 ETF holds 4.6498 million shares, having decreased its holdings by 70,900 shares compared to the previous period [3].

Core Insights - Innovation Medical's stock price decreased by 2.03% on November 19, trading at 21.24 CNY per share with a total market capitalization of 9.373 billion CNY [1] - The company has seen a significant stock price increase of 166.83% year-to-date, but has experienced declines of 9.50% over the last five trading days, 9.69% over the last twenty days, and 14.49% over the last sixty days [1] - The company has been active in the stock market, appearing on the "Dragon and Tiger List" 19 times this year, with the most recent appearance on October 20, where it recorded a net buy of 242 million CNY [1] Financial Performance - For the period from January to September 2025, Innovation Medical reported a revenue of 597 million CNY, a year-on-year decrease of 2.11%, while the net profit attributable to shareholders was 4.7244 million CNY, reflecting a year-on-year increase of 116.97% [2] - The company has a primary business focus on medical services, which accounts for 99.73% of its revenue, with other income contributing only 0.27% [1] Shareholder Information - As of September 30, the number of shareholders for Innovation Medical reached 130,200, an increase of 58.75% from the previous period, while the average number of circulating shares per shareholder decreased by 37.01% to 3,196 shares [2] Dividend Information - Since its A-share listing, Innovation Medical has distributed a total of 55.8729 million CNY in dividends, with no dividends paid in the last three years [3]

Company Overview - Harbin Sanlian Pharmaceutical Co., Ltd. is located in Harbin, Heilongjiang Province, established on June 21, 1996, and listed on September 22, 2017. The company specializes in the research, production, and sales of chemical drug formulations [1][2]. Financial Performance - As of November 10, 2023, Harbin Sanlian reported a revenue of 581 million yuan for the period from January to September 2025, a year-on-year decrease of 30.75%. The net profit attributable to the parent company was -209 million yuan, a significant decline of 614.61% [2]. - The company has cumulatively distributed 677 million yuan in dividends since its A-share listing, with 158 million yuan distributed over the past three years [3]. Stock Performance - On November 18, 2023, Harbin Sanlian's stock price increased by 2.34%, reaching 14.89 yuan per share, with a trading volume of 52.42 million yuan and a turnover rate of 2.05%. The total market capitalization stood at 4.711 billion yuan [1]. - Year-to-date, the stock price has risen by 54.30%, with a 2.69% increase over the last five trading days and a 12.12% increase over the last 20 days. However, it has seen a decline of 1.72% over the past 60 days [1]. Shareholder Information - As of November 10, 2023, the number of shareholders for Harbin Sanlian was 39,600, a decrease of 2.98% from the previous period. The average number of circulating shares per person increased by 3.07% to 4,419 shares [2]. Business Segmentation - The main revenue sources for Harbin Sanlian include: large-volume injections (32.00%), lyophilized powder injections (18.39%), solid preparations (17.39%), small-volume injections (14.34%), and other segments such as veterinary drugs (2.55%) and import/export trade (1.82%) [1].

11月17日，安科生物盘中下跌2.03%，截至10:04，报10.61元/股，成交1.13亿元，换手率0.86%，总市值 177.45亿元。 安科生物所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：民营医院、基因测 序、互联医疗、医疗美容、肝炎治疗等。 截至10月31日，安科生物股东户数7.69万，较上期增加4.63%；人均流通股15886股，较上期减少 4.43%。2025年1月-9月，安科生物实现营业收入19.63亿元，同比增长2.15%；归母净利润5.51亿元，同 比减少6.48%。 分红方面，安科生物A股上市后累计派现26.62亿元。近三年，累计派现12.52亿元。 机构持仓方面，截止2025年9月30日，安科生物十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1952.26万股，相比上期减少126.90万股。招商国证生物医药指数A（161726）位居第五大 流通股东，持股1596.17万股，相比上期减少273.29万股。创新药（159992）位居第七大流通股东，持股 1121.77万股，相比上期增加19.13万股。南方中证1000ETF（512100）位居第九大流通 ...

Core Viewpoint - 康德莱's stock price has shown a year-to-date increase of 32.29%, but it has recently experienced a slight decline in the short term [2]. Group 1: Stock Performance - As of November 17, 康德莱's stock price decreased by 2.11% to 9.30 yuan per share, with a trading volume of 21.77 million yuan and a turnover rate of 0.53%, resulting in a total market capitalization of 4.062 billion yuan [1]. - In the past five trading days, 康德莱's stock has dropped by 1.06%, while it has increased by 1.97% over the last 20 days and 4.49% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, 康德莱 reported a revenue of 1.721 billion yuan, reflecting a year-on-year growth of 0.95%, and a net profit attributable to shareholders of 194 million yuan, which is a 17.27% increase year-on-year [3]. - Since its A-share listing, 康德莱 has distributed a total of 530 million yuan in dividends, with 231 million yuan distributed over the past three years [4]. Group 3: Shareholder and Institutional Holdings - As of September 30, 2025, 康德莱 had 34,100 shareholders, an increase of 29.67% from the previous period, with an average of 12,826 circulating shares per shareholder, down by 22.88% [3]. - Among the top ten circulating shareholders, 招商成长量化选股股票A and 医疗器械ETF are new entrants, holding 2.4635 million shares and 1.8815 million shares, respectively [4].

Group 1 - The stock price of Harbin Sanlian Pharmaceutical Co., Ltd. (哈三联) increased by 2.00% on November 14, reaching 15.29 CNY per share, with a trading volume of 1.51 billion CNY and a turnover rate of 5.70%, resulting in a total market capitalization of 48.37 billion CNY [1] - Year-to-date, the stock price has risen by 58.45%, with a 10.00% increase over the last five trading days, a 16.63% increase over the last 20 days, and a 2.55% increase over the last 60 days [2] - The company has appeared on the "龙虎榜" (a stock market leaderboard) nine times this year, with the most recent appearance on June 3 [2] Group 2 - The company's main business revenue composition includes: large-volume infusion (32.00%), lyophilized powder injection (18.39%), solid preparations (17.39%), small-volume injections (14.34%), and others [2] - As of November 10, the number of shareholders is 39,600, a decrease of 2.98% from the previous period, while the average circulating shares per person increased by 3.07% to 4,419 shares [2] - For the period from January to September 2025, the company reported a revenue of 581 million CNY, a year-on-year decrease of 30.75%, and a net profit attributable to shareholders of -209 million CNY, a year-on-year decrease of 614.61% [2] Group 3 - Since its A-share listing, the company has distributed a total of 677 million CNY in dividends, with 158 million CNY distributed over the past three years [3]